×

Augmented designs to assess immune response in vaccine trials. (English) Zbl 1114.62116

Summary: This article introduces methods for use in vaccine clinical trials to help determine whether the immune response to a vaccine is actually causing a reduction in the infection rate. This is not easy because immune response to the (say HIV) vaccine is only observed in the HIV vaccine arm. If we knew what the HIV-specific immune response in placebo recipients would have been, had they been vaccinated, this immune response could be treated essentially like a baseline covariate and an interaction with treatment could be evaluated. Relatedly, the rate of infection by this baseline covariate could be compared between the two groups and a causative role of immune response would be supported if infection risk decreased with increasing HIV immune response only in the vaccine group.
We introduce two methods for inferring this HIV-specific immune response. The first involves vaccinating everyone before baseline with an irrelevant vaccine, for example, rabies. Randomization ensures that the relationship between the immune responses to the rabies and HIV vaccines observed in the vaccine group is the same as what would have been seen in the placebo group. We infer a placebo volunteer’s response to the HIV vaccine using their rabies response and a prediction model from the vaccine group. The second method entails vaccinating all uninfected placebo patients at the closeout of the trial with the HIV vaccine and recording immune response. We pretend this immune response at closeout is what they would have had at baseline. We can then infer what the distribution of immune response among placebo infecteds would have been. Such designs may help elucidate the role of immune response in preventing infections. More pointedly, they could be helpful in the decision to improve or abandon an HIV vaccine with mediocre performance in a phase III trial.

MSC:

62P10 Applications of statistics to biology and medical sciences; meta analysis
92C60 Medical epidemiology
PDFBibTeX XMLCite
Full Text: DOI Link

References:

[1] Carey, Bayesian inference on protective antibody levels using case-control data, Biometrics 57 pp 135– (2001) · Zbl 1209.62263 · doi:10.1111/j.0006-341X.2001.00135.x
[2] Chan, Use of statistical models for evaluating antibody response as a correlate of protection against varicella, Statistics in Medicine 21 pp 3411– (2002) · doi:10.1002/sim.1268
[3] Chan, Encyclopedia of Biopharmaceutical Statistics pp 1005– (2003) · doi:10.1201/b14760-141
[4] Follmann, On the effect of treatment among treatment compliers: An analysis of the Multiple Risk Factor Intervention Trial, Journal of the American Statistical Association 95 pp 1101– (2000) · Zbl 1009.62098 · doi:10.2307/2669746
[5] Frangakis, Principal stratification in causal inference, Biometrics 58 pp 21– (2002) · Zbl 1209.62288 · doi:10.1111/j.0006-341X.2002.00021.x
[6] Gilbert, Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials, Biometrics 59 pp 531– (2003) · Zbl 1210.62161 · doi:10.1111/1541-0420.00063
[7] Gilbert, Correlation between immunologic responses to rgp120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial, Journal of Infectious Diseases 191 pp 666– (2005) · doi:10.1086/428405
[8] Graham, Lessons from failure-Preparing for future HIV-1 vaccine efficacy trials, Journal of Infectious Diseases 191 pp 647– (2005) · doi:10.1086/428406
[9] Halloran, Encyclopedia of Biostatistics 6 pp 4687– (1998)
[10] Halloran, Causal inference in infectious diseases, Epidemiology 6 pp 142– (1995) · doi:10.1097/00001648-199503000-00010
[11] Hallstrom, Patients at lower risk of arrhythmia recurrence: A subgroup in whom implantable defibrillators may not offer benefit, Journal of the American College of Cardiology 37 pp 1093– (2001) · doi:10.1016/S0735-1097(00)01208-0
[12] Hudgens, Causal vaccine effects on binary post-infection outcomes (2004)
[13] Hudgens, On the analysis of viral load endpoints in HIV vaccine trials, Statistics in Medicine 22 pp 2281– (2003) · Zbl 1210.62161 · doi:10.1002/sim.1394
[14] Lachenbruch, Encyclopedia of Biopharmaceutical Statistics pp 47– (2000)
[15] Nabel, Challenges and opportunities for development of an HIV vaccine, Nature 410 pp 1002– (2001) · doi:10.1038/35073500
[16] Plikaytis, Statistical considerations for vaccine immunogenicity trials. Part 2: Noninferiority and other statistical approaches to vaccine evaluation, Vaccine 23 pp 1606– (2005) · doi:10.1016/j.vaccine.2004.06.047
[17] Prentice, Surrogate endpoints in clinical trials: Definition and operational criteria, Statistics in Medicine 8 pp 431– (1989) · doi:10.1002/sim.4780080407
[18] The rgp120 HIV Vaccine Study Group, Placebo-controlled trial of a recombinant glycoprotein 120 vaccine to prevent HIV infection, Journal of Infectious Diseases 191 pp 654– (2005) · doi:10.1086/428404
[19] Rubin, Estimating causal effects of treatments in randomized and nonrandomized studies, Journal of Educational Psychology 66 pp 688– (1974) · doi:10.1037/h0037350
[20] Rubin, Assignment to a treatment group on the basis of a covariate, Journal of Educational Statistics 2 pp 1– (1977) · doi:10.2307/1164933
[21] Rubin, Bayesian inference for causal effects, Annals of Statistics 6 pp 34– (1978) · Zbl 0383.62021 · doi:10.1214/aos/1176344064
This reference list is based on information provided by the publisher or from digital mathematics libraries. Its items are heuristically matched to zbMATH identifiers and may contain data conversion errors. In some cases that data have been complemented/enhanced by data from zbMATH Open. This attempts to reflect the references listed in the original paper as accurately as possible without claiming completeness or a perfect matching.